Company intelligence / Profile preview

ProChon Biotech

Woburn, Massachusetts, United Statespmc.ncbi.nlm.nih.gov ↗

Ownership: Private
Development stage: Preclinical

Overview

ProChon's BioCart™II, a scaffold seeded with autologous chondrocytes for knee cartilage repair, reached Phase II clinical trials and was approved in Greece. The company also developed FGFR3 antagonists for multiple myeloma at the preclinical stage. ProChon was acquired by Histogenics in May 2011 to combine regenerative medicine pipelines focused on orthopedics and related surgical applications.

Therapeutic areas: OncologyRare DiseasesRheumatology
Modalities: Cell therapyMonoclonal antibodyRecombinant protein (growth factors)Scaffold-based tissue engineering (biocompatible scaffold)
Industry: Biotech

Partnerships

Altima PartnersBoston Millennia PartnersFoundation Medical PartnersStryker Corporation

Beyond the preview

Go deeper on ProChon Biotech.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ProChon Biotech.

Explore the full profile